Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total revenue, net	$ 140	$ 796	$ 1,939	$ 4,555
Operating expenses:
Cost of product sold	6	1,236	33	6,059
Research and development	8,302	17,521	32,653	55,589
Selling, general and administrative	8,803	8,825	21,612	29,933
Total operating expenses	17,111	27,582	54,298	91,581
Loss from operations	(16,971)	(26,786)	(52,359)	(87,026)
Other income, net	1,289	765	3,812	943
Net loss and comprehensive loss	$ (15,682)	$ (26,021)	$ (48,547)	$ (86,083)
Net loss per share - basic	$ (8.62)	$ (14.44)	$ (26.73)	$ (47.91)
Net loss per share - diluted	$ (8.62)	$ (14.44)	$ (26.73)	$ (47.91)
Weighted average shares basic	1,819,066	1,801,391	1,816,294	1,796,800
Weighted average shares diluted	1,819,066	1,801,391	1,816,294	1,796,800
Grant
Revenue	$ 64	$ 66	$ 1,678	$ 1,010
Product revenue, net
Revenue	$ 76	$ 730	$ 261	$ 3,545